OraSure Technologies (NASDAQ:OSUR) has been awarded
a $710,310 contract from the Biomedical Advanced Research and
Development Authority (BARDA) to develop a pan-SARS-coronavirus antigen
rapid in-home self-test that uses oral fluid samples and provides
results in 20 minutes.
This support will enable OraSure to file for FDA
Emergency Use Authorization allowing for an in-home self-test to debut
into the U.S.
Shares are up 9% premarket.
https://seekingalpha.com/news/3558493-orasure-nabs-barda-contract-for-in-home-covidminus-19-test-shares-up-9-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.